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Although the promise of antitumour iron chelation therapy of cancer (ICT) is widely recognised, to 
date the potential of iron−chelators (ICs) in skin cancer has not been properly explored. A key 
challenge to be addressed is the observation in both animal and clinical trials that the antitumour 
properties of currently available ICs may be accompanied by severe toxic side effects upon 
repeated systemic administration. Further optimization of the dose, period of treatment and mode 
of administration therefore seems crucial for the success of ICT. The lipophilic nature of 
thiosemicarbazone ICs of the di−2−pyridyl− (i.e. Dp) and 2−benzoylpyrindine− (i.e. Bp) series 
makes them potentially attractive for treatment of non−melanoma skin cancer via topical 
application (1). As a first step towards this goal, in the present study, we investigated the 
antiproliferative potential of the Dp− and Bp− thiosemicarbazone analogues Dp44mT, Dp4pT, 
Bp4eT and Bp4pT using the human primary fibroblast cell line FEK4 and the spontaneously 
immortalised human keratinocyte cell line, HaCaT as models. The HaCaT cell line has proved a 
useful and reliable in vitro model of human skin cell carcinoma. This cell line is hyperproliferative 
and shows a significantly higher proliferation rate compared to normal human skin keratinocytes 
and FEK4 fibroblasts. The time−course and dose response studies with MTT assay revealed that 
both Bp− and Dp− analogues have a more pronounced growth inhibitory effect in HaCaT cancer 
cells than in normal FEK4 fibroblasts. The average IC50 values of the compounds in HaCaT cells 
were in the nanomolar range (i.e. 0.05−0.5 uM), while in FEK4 cells the average IC50 values 
were in the micromolar range (i.e. 1−5 uM). In HaCaT cells, Bp4pT appeared to be the most 
potent antiproliferative chelator with IC50 = 0.05 uM. In contrast in FEK4 cells, both Bp analogues 
and DP4pT yielded the same IC50 value of 1 uM. Moreover in FEK4 cells, Dp44mT appeared to 
be the least effective antiproliferative chelator (IC50 = 5uM). Nevertheless the IC50 values of the 
Bp− and Dp− thiosemicarbazones in both cell lines used in this study were 50−200 times lower 
than those obtained with desferrioxamine (DFO) and salicylaldehyde isonicotinoyl hydrazone 
(SIH) chelators with the same cell lines in this laboratory. In an attempt to relate these findings to 
an in vivo setting, clone forming assays were performed in parallel and the results showed that in 
agreement with MTT data, both Bp− and Dp−analogues have substantially higher antiproliferative 
activity than DFO and SIH. We also analysed the impact of the chelators on the cell cycle by flow 
cytometry, using bromodeoxyuridine incorporation. The results showed that both Dp− and Bp− 
analogues had an effective impact on the cell cycle in HaCaT cells with concentrations that were 
100−200− fold lower than those necessary to obtain the same effect with SIH and DFO. The 
strong antiproliferative activities observed for both Dp− and Bp− chelators, together with their 
lipophilicity, therefore provide a rationale for their use in topical ICT of non−melanoma skin 
cancer.  
   1. Yu Y, Kalinowski DS, Kovacevic Z, Siafakas AR, Jansson PJ; Stefani C, Lovejoy DB, 
Sharpe PC, Bernhardt PV, Richardson DR. J. Med. Chem. 2009, 52:5271−5294.  
